University of Kansas Alzheimer's Disease Research Center (KU ADRC)

摘要：总体 堪萨斯大学阿尔茨海默病研究中心(KU ADRC)促进阿尔茨海默氏症 在地方、国家和国际层面开展疾病和相关疾病(ADRD)研究。我们的优势在于 基础和翻译线粒体、生活方式改变和预防研究定义了新陈代谢的主题 在过去的十年里，我们一直在追求和改进。我们拥有先进和成熟的基础设施， 促进更好地了解阿尔茨海默病，更好地照顾受影响的人，以及新的治疗干预措施。这个 Ku ADRC将在下一个周期使用其智力和基础设施资产来推动一所大学的AD研究 并为我们的成功进行投资，这样做将使这一领域更接近治愈方法。 我们的中心无缝地在长凳和床边之间移动，无论是就我们的研究项目而言，我们 支持，以及支持调查员项目所需的基础设施。生活方式干预研究 产生我们呼吁湿实验室调查人员解决的基本机械问题，以及 临床实施和实践现在是干燥实验室、临床和医疗保健交付的重点 调查人员。针对阿尔茨海默病线粒体成分的研究表明线粒体基因的作用 在阿尔茨海默病风险中，线粒体在细胞蛋白平衡和蛋白质聚集、特定连接 线粒体和AD标志蛋白之间的关系，以及如何通过 生活方式和药理学方法。到目前为止，这些努力使我们创造出了构成 独特的治疗途径和临床试验基础设施，支持对新陈代谢的实际研究 对实际AD患者的干预。 在2021-26年周期中，我们将使用我们的智力和基础设施资产来解决 广告领域，包括基础知识和护理实施方面的差距。在这个周期中，KU ADRC 将致力于(1)支持创新的AD和大脑老化研究、教育和临床计划；(2)推动 定义领域的新陈代谢研究，以及(3)将实用和新颖的新陈代谢导向疗法带给 床边和诊所。

ABSTRACT: OVERALL The University of Kansas Alzheimer's Disease Research Center (KU ADRC) promotes Alzheimer's Disease and Related Disorders (ADRD) research at local, national, and international levels. Our strengths in basic and translational mitochondria, lifestyle modification, and prevention research define a metabolism theme we pursued and refined over the past decade. We boast a sophisticated and mature infrastructure that advances a better understanding of AD, better care of affected persons, and new treatment interventions. The KU ADRC will use its intellectual and infrastructure assets this next cycle to drive AD research at a university vested and investing in our success, and in doing so move the field closer to a cure. Our Center moves seamlessly between bench and bedside, both in terms of the research projects we support, and in the infrastructure required to back investigator projects. Lifestyle intervention research generates fundamental mechanistic questions we call on wet lab investigators to address, and questions of clinical implementation and practice are now the focus of dry lab, clinical, and health care delivery investigators. Research addressing AD's mitochondrial component demonstrate a role for mitochondrial genes in AD risk, that mitochondria play a critical role in cell proteostasis and protein aggregation, specific links between mitochondria and AD hallmark proteins, and how to manipulate brain energy metabolism through lifestyle and pharmacologic approaches. To date these efforts led us to create novel compounds that constitute a unique therapeutic pipeline, and clinical trial infrastructure that supports actual studies of metabolism interventions in actual AD patients. For the 2021-26 cycle we will use our intellectual and infrastructure assets to address critical gaps in the AD field, including gaps in fundamental knowledge and care implementation. During this cycle the KU ADRC will work to (1) Empower innovative AD and brain aging research, education, and clinical programs; (2) Drive field-defining metabolism research, and (3) Bring practical and novel metabolism-directed therapies to the bedside and clinic.